The estimated Net Worth of Patrick L Keran is at least $1.56 Milión dollars as of 1 January 2023. Mr. Keran owns over 5,280 units of SeaSpine Corp stock worth over $693,901 and over the last 9 years he sold SPNE stock worth over $0. In addition, he makes $868,486 as Vice President, General Counsel a Secretary at SeaSpine Corp.
Patrick has made over 5 trades of the SeaSpine Corp stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 5,280 units of SPNE stock worth $50,371 on 1 January 2023.
The largest trade he's ever made was exercising 30,834 units of SeaSpine Corp stock on 1 January 2020 worth over $294,156. On average, Patrick trades about 2,891 units every 46 days since 2015. As of 1 January 2023 he still owns at least 72,736 units of SeaSpine Corp stock.
You can see the complete history of Mr. Keran stock trades at the bottom of the page.
Patrick L. Keran J.D. serves as Vice President, General Counsel, Secretary of the Company. Prior to joining SeaSpine, Mr. Keran provided strategic and business advisory services to a variety of life sciences companies, including acting as Chief Legal Officer to NAIA Pharmaceuticals, Inc., a privately held international drug development company. From February 2010 to February 2015, Mr. Keran served as president and chief operating officer of Mast Therapeutics, Inc., a publicly held clinical stage biopharmaceutical company, and from August 2006 to February 2010, he served as its general counsel. He also served as Mast’s secretary from September 2006 to February 2015 and served as its principal financial officer from July 2009 to January 2013. Previously, from 2004 to 2006, Mr. Keran was associate general counsel at Ionis Pharmaceuticals, Inc. (formerly known as Isis Pharmaceuticals, Inc.), a publicly held drug discovery and development company. From 1999 to 2004, Mr. Keran practiced corporate law at the law firms of Heller Ehrman LLP and Brobeck Phleger & Harrison LLP, specializing in public and private financings, licensing arrangements, mergers and acquisitions and corporate governance matters. Mr. Keran is licensed to practice law in the State of California. Mr. Keran received a B.A. from the University of California at San Diego and a J.D. from the University of California at Berkeley, Boalt Hall School of Law.
As the Vice President, General Counsel a Secretary of SeaSpine Corp, the total compensation of Patrick Keran at SeaSpine Corp is $868,486. There are 4 executives at SeaSpine Corp getting paid more, with Keith Valentine having the highest compensation of $1,840,570.
Patrick Keran is 48, he's been the Vice President, General Counsel a Secretary of SeaSpine Corp since 2016. There are 18 older and 3 younger executives at SeaSpine Corp. The oldest executive at SeaSpine Holdings Corp is Keith Bradley, 75, who is the Independent Director.
Patrick's mailing address filed with the SEC is 3451 PLANO PARKWAY, , LEWISVILLE, TX, 75056.
Over the last 9 years, insiders at SeaSpine Corp have traded over $2,659,931 worth of SeaSpine Corp stock and bought 297,805 units worth $3,591,897 . The most active insiders traders include Stuart Essig, Richard E Caruso a Keith Valentine. On average, SeaSpine Corp executives and independent directors trade stock every 39 days with the average trade being worth of $151,762. The most recent stock trade was executed by John J. Winge on 1 January 2023, trading 4,868 units of SPNE stock currently worth $46,441.
SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine's orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine's spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in both orthobiologic sciences and spinal implants product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide.
SeaSpine Corp executives and other stock owners filed with the SEC include: